Advertisement
Research Article| Volume 1, ISSUE 3, P501-522, September 1981

Antiarrhythmic Drug Monitoring

  • Joan H. Howanitz
    Correspondence
    Corresponding author: Division of Clinical Pathology, Department of Pathology, State University of New York, Upstate Medical Center, 750 East Adams Street, Syracuse, New York 13210
    Affiliations
    Assistant Professor of Pathology, State University of New York, Upstate Medical Center College of Medicine, Syracuse, New York

    Assistant Director of Clinical Pathology, University Hospital of Upstate Medical Center, Syracuse, New York
    Search for articles by this author
  • Peter J. Howanitz
    Affiliations
    Assistant Director of Clinical Pathology, University Hospital of Upstate Medical Center, Syracuse, New York

    Assistant Professor of Pathology, State University of New York, Upstate Medical Center College of Medicine, Syracuse, New York
    Search for articles by this author
DOI:https://doi.org/10.1016/S0272-2712(18)31087-4
Antiarrhythmic Drug Monitoring
Previous ArticleAntiepileptic Therapeutic Drug Monitoring
Next ArticleDigitalis and Vasoactive Drugs
      This paper is only available as a PDF. To read, Please Download here.
      The classification of antiarrhythmic agents by mechanism of action aids the clinician in selecting appropriate antiarrhythmic drug therapy. The pharmacokinetics, the side effects, and the interpretation of serum levels of quinidine, procainamide, disopyramide, lidocaine, and other agents are discussed.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Ambler P.K.
        • Singh B.N.
        • Lever M.
        A simple and rapid fluorometric method for the estimation of 1-(2-hydroxy-3-isopropylamino-propoxy)-naphthalene hydrochloride, propranolol, in blood.
        Clin. Chim. Acta. 1974; 54: 373
        • Anderson J.L.
        • Harrison D.C.
        • Meffin P.J.
        • et al.
        Antiarrhythmic drugs: Clinical pharmacology and therapeutic uses.
        Drugs. 1978; 15: 271
        • Antman E.M.
        • Stone P.H.
        • Muller J.E.
        • et al.
        Calcium channel blocking agents in the treatment of cardiovascular disorders. Part I: Basic and clinical electrophysiologic effects.
        Ann. Intern. Med. 1980; 93: 875
        • Atkinson A.J.
        • Davison R.
        Diphenylhydantoin as an antiarrhythmic drug.
        Annu. Rev. Med. 1974; 25: 99
        • Atkinson A.J.
        • Parker M.
        • Strong J.
        Rapid gas chromatographic measurement of plasmaprocainamide concentration.
        Clin. Chem. 1972; 18: 643
        • Atkinson A.J.
        • Strong J.M.
        Effect of active drug metabolites on plasma level-response correlations.
        J. Pharmacokinet. Biopharm. 1977; 5: 95
        • Benowitz N.L.
        • Meister W.
        Clinical pharmacokinetics of lignocaine.
        Clin. Pharmacokinet. 1978; 3: 177
        • Bigger J.T.
        • Schmidt D.H.
        • Kutt H.
        Relationship between plasma level of diphenylhydantoin sodium and its cardiac antiarrhythmic effects.
        Circulation. 1968; 38: 363
        • Bolme P.
        • Otto U.
        Dose-dependence of the pharmacokinetics of quinidine.
        Eur. J. Clin. Pharmacol. 1977; 12: 73
        • Broussard L.A.
        • Frings C.S.
        Quantitative high-performance liquid-chromatographic method for determining disopyramide (Norpace) in serum.
        Clin. Toxicol. 1979; 14: 579
        • Buckman K.
        • Claiborne K.
        • de Guzman M.
        • et al.
        Lidocaine efficacy and toxicity assessed by a new, rapid method.
        Clin. Pharmacol. Ther. 1980; 28: 177
        • Buiumsohn A.
        • Eisenberg E.S.
        • Jacob H.
        • et al.
        Seizures and intraventricular conduction defect in propranolol poisoning.
        Ann. Intern. Med. 1979; 91: 860
        • Carliner N.H.
        • Crouthamel W.G.
        • Fisher M.L.
        • et al.
        Guinidine therapy in hospitalized patients with ventricular arrhythmias.
        Am. Heart J. 1979; 98: 708
        • Check W.A.
        Calcium antagonists: Long-awaited new therapy for heart disease.
        J. A. M. A. 1981; 245: 807
        • Collinsworth K.A.
        • Strong J.M.
        • Atkinson A.J.
        • et al.
        Pharmacokinetics and metabolism of lidocaine in patients with renal failure.
        Clin. Pharmacol. Ther. 1975; 18: 59
        • Cotham R.H.
        • Shand D.G.
        Spuriously low plasma propranolol concentrations resulting from blood collection methods.
        Clin. Pharmacol. Ther. 1975; 18: 535
        • Cramer G.
        • Isaksson B.
        Quantitative determination of quinidine in plasma.
        Scand. J. Clin. Lab. Invest. 1963; 15: 553
        • Craxi A.
        • Gatto G.
        • Maringhini A.
        • et al.
        Disopyramide and cholestasis.
        Ann. Intern. Med. 1980; 93: 150
        • Danilo P.
        Aprindine.
        Am. Heart J. 1979; 97: 119
        • Danilo P.
        Tocainide.
        Am. Heart J. 1979; 97: 259
        • David B.M.
        • Madsen B.W.
        • Ilett K.F.
        Plasma binding of disopyramide.
        Br. J. Clin. Pharmacol. 1980; 9: 614
        • DiSalle E.
        • Baker K.M.
        • Bareggi S.R.
        • et al.
        The sensitive gas chromatrographic method for the determination of propranolol in human plasma.
        J. Chromatogr. 1973; 84: 347
        • Doering W.
        Quinidine-digoxin interaction.
        N. Engl. J. Med. 1979; 301: 400
        • Drayer D.E.
        • Hughes M.
        • Lorenzo B.
        • et al.
        Prevalence of high (3S)-3-hydroxyquinidine/quinidine ratios in serum, and clearance of quinidine in cardiac patients with age.
        Clin. Pharmacol. Ther. 1980; 27: 72
        • Drayer D.E.
        • Lorenzo B.
        • Reidenberg M.M.
        Liquid chromatography and fluorescence spectroscopy compared with a homogeneous enzyme immunoassay technique for determining quinidine in serum.
        Clin. Chem. 1981; 27: 308
        • Drayer D.E.
        • Lowenthal D.T.
        • Restivo K.M.
        • et al.
        Steady-state serum levels of quinidine and active metabolites in cardiac patients with varying degrees of renal function.
        Clin. Pharmacol. Ther. 1978; 24: 31
        • Duchateau A.M.J.A.
        • Merkus F.W.H.M.
        • Schobben F.
        Rapid gas chromatographic determination of disopyramide in serum using a nitrogen detector.
        J. Chromatogr. 1975; 109: 432
        • du Souich P.
        • Erill S.
        Metabolism of procainamide and p-aminobenzoic acid in patients with chronic liver disease.
        Clin. Pharmacol. Ther. 1977; 22: 588
        • Dutcher J.S.
        • Strong J.M.
        • Lucas S.V.
        • et al.
        Procainamide and N-acetylprocainamide kinetics investigated simultaneously with stable isotope methodology.
        Clin. Pharmacol. Ther. 1977; 22: 447
        • Ellrodt G.
        • Singh B.N.
        Adverse effects of disopyramide (Norpace): Toxic interactions with other antiarrhythmic agents.
        Heart Lung. 1980; 9: 469
        • Elson J.
        • Strong J.M.
        • Lee W.
        • et al.
        Antiarrhythmic potency of N-acetylprocainamide.
        Clin. Pharmacol. Ther. 1975; 17: 134
        • Fanciullo R.A.
        • Huber N.
        • Izutsu A.
        • et al.
        Homogeneous enzyme immunoassay for procainamide in serum.
        Clin. Chem. 1978; 24: 1056
        • Feely J.
        • Wilkinson G.R.
        • Wood A.J.J.
        Reduction of liver blood flow and propranolol metabolism by Cimetidine.
        N. Engl. J. Med. 1981; 304: 692
        • Fremstad D.
        • Nilsen O.G.
        • Storstein L.
        • et al.
        Pharmacokinetics of quinidine related to plasma protein binding in man.
        Eur. J. Clin. Pharmacol. 1979; 15: 187
        • Giardina E.V.
        • Dreyfuss J.
        • Bigger J.T.
        • et al.
        Metabolism of procainamide in normal and cardiac subjects.
        Clin. Pharmacol. Ther. 1976; 19: 339
        • Goldberg I.J.
        • Brown L.K.
        • Rayfield E.J.
        Disopyramide (Norpace)-induced hypoglycemia.
        Am. J. Med. 1980; 69: 463
        • Guentert T.W.
        • Coates P.E.
        • Upton R.A.
        • et al.
        Determination of quinidine and its major metabolites by high-performance liquid chromatography.
        J. Chromatogr. 1979; 162: 59
        • Hayler A.M.
        • Holt D.W.
        • Volans G.N.
        Fatal overdosage with disopyramide.
        Lancet. 1978; 1: 968
        • Hayler A.M.
        • Medd R.K.
        • Holt D.W.
        • et al.
        Experimental disopyramide poisoning: Treatment by cardiovascular support and with charcoal hemoperfusion.
        J. Pharmacol. Exp. Ther. 1979; 211: 491
        • Heel R.C.
        • Brogden R.N.
        • Speight T.M.
        • et al.
        Disopyramide: A review of its pharmacological properties and therapeutic use in treating cardiac arrhythmias.
        Drugs. 1978; 15: 331
        • Heissenbuttel R.H.
        • Bigger J.T.
        Bretylium Tosylate: A newly available antiarrhythmic drug for ventricular arrhythmias.
        Ann. Intern. Med. 1979; 91: 229
        • Holt D.W.
        • Walsh A.C.
        • Curry P.V.
        • et al.
        Paediatric use of mexiletine and disopyramide.
        Lancet. 1979; 2: 377
        • Hutsell T.C.
        • Stachelski S.J.
        Determination of disopyramide and its mono-N-dealkylated metabolite in blood serum and urine.
        J. Chromatogr. 1975; 106: 151
        • Izutsu A.
        • Pirio M.R.
        • Buckley N.
        • et al.
        Homogeneous enzyme immunoassay for N-acetylprocainamide in serum.
        Clin. Chem. 1978; 24: 1055
        • Karim A.
        The pharmacokinetics of Norpace.
        Angiology. 1975; 26: 85
        • Karlsson E.
        Clinical pharmacokinetics of procainamide.
        Clin. Pharmacokinet. 1978; 3: 97
        • Karlsson E.
        Procainamide and phenytoin: Comparative study of their antiarrhythmic effects at apparent therapeutic plasma levels.
        Br. Heart J. 1975; 37: 731
        • Kates R.E.
        Therapeutic monitoring of antiarrhythmic drugs.
        Ther. Drug Monitor. 1980; 2: 119
        • Kessler K.M.
        • Leech R.C.
        • Spann J.F.
        Blood collection techniques, heparin and quinidine protein binding.
        Clin. Pharmacol. Ther. 1979; 25: 204
        • Kessler K.M.
        • Lowenthal D.T.
        • Warner H.
        • et al.
        Quinidine elimination in patients with congestive heart failure or poor renal function.
        N. Engl. J. Med. 1974; 290: 706
        • Kinney E.L.
        • Field E.H.
        • Salmon M.P.
        • et al.
        Cardiac arrhythmias associated with disopyramide.
        N. Engl. J. Med. 1980; 302: 1146
        • Kirkpatrick B.
        • Chegwidden K.
        • Colvin W.
        • et al.
        Homogeneous enzyme immunoassay for disopyramide in human serum.
        Ligand Q. 1980; 3: 50
        • Koch-Weser J.
        Disopyramide.
        N. Engl. J. Med. 1979; 300: 957
        • Koch-Weser J.
        Serum procainamide levels as therapeutic guides.
        Clin. Pharmacokinet. 1977; 2: 389
        • Koch-Weser J.
        • Klein S.W.
        Procainamide dosage schedules, plasma concentrations, and clinical effects.
        J. A. M. A. 1971; 215: 1454
        • Lahita R.
        • Kluger J.
        • Drayer D.E.
        • et al.
        Antibodies to nuclear antigens in patients treated with procainamide or acetylprocainamide.
        N. Engl. J. Med. 1979; 301: 1382
        • Landmark K.
        • Storstein L.
        • Larsen A.
        Disopyramide plasma levels in cardiac patients on maintenance therapy.
        Acta Med. Scand. 1979; 206: 385
        • Lehane D.P.
        • Wissert P.J.
        • Menyharth P.
        • et al.
        Enzyme immunoassay for serum lidocaine in antiarrhythmic therapy.
        Clin. Chem. 1979; 25: 614
        • Lewis P.
        The essential action of propranolol in hypertension.
        Am. J. Med. 1976; 60: 837
        • Lertora J.J.L.
        • Atkinson A.J.
        • Kushner W.
        • et al.
        Long-term antiarrhythmic therapy with N-acetylprocainamide.
        Clin. Pharmacol. Ther. 1979; 25: 273
        • Louis S.
        • Kutt H.
        • McDowell F.
        The cardiocirculatory changes caused by intravenous Dilantin and its solvent.
        Am. Heart J. 1967; 74: 523
        • Lown B.
        • Graboys T.B.
        • Podrid P.J.
        • et al.
        Effect of a digitalis drug on ventricular premature beats.
        N. Engl. J. Med. 1977; 296: 301
        • Martin D.
        • Burke L.
        • Nordin W.
        • et al.
        A simple spectrophotometric method for disopyramide phosphate (Norpace) measurement in biological fluids.
        Clin. Chem. 1978; 24: 991
        • Mason W.D.
        • Amick E.N.
        • Weddle O.H.
        Rapid determination of propranolol and 4-hydroxypropranolol in plasma by high pressure liquid chromatography.
        Anal. Lett. 1977; 10: 515
        • Matusik E.
        • Gibson T.P.
        Fluorometric assay for N-acetylprocainamide.
        Clin. Chem. 1975; 21: 1899
        • Meitzer R.S.
        • Robert E.W.
        • McMorrow M.
        • et al.
        Atypical ventricular tachycardia as a manifestation of disopyramide toxicity.
        Am. J. Cardiol. 1978; 42: 1049
        • Multiple authors
        Treatment of ventricular arrhythmias: Role of mexiletine. (Lequime, J., and Pannier, R., eds.).
        Acta Cardiol.,. 1980; 15 (Suppl): 1-145
        • Narang P.K.
        • Crouthamel W.G.
        • Carliner N.H.
        • et al.
        Lidocaine and its active metabolites.
        Clin. Pharmacol. Ther. 1978; 24: 654
        • Niarchos A.P.
        Disopyramide: Serum level and arrhythmia conversion.
        Am. Heart J. 1976; 92: 57
        • Nicholson W.J.
        • Martin C.E.
        • Gracey J.G.
        • et al.
        Disopyramide-induced ventricular fibrillation.
        Am. J. Cardiol. 1979; 43: 1053
        • Nies A.S.
        • Gal J.
        • Gerber J.G.
        Complications of disopyramide therapy.
        Lancet. 1979; 1: 330
        • Nygard G.
        • Shelver W.H.
        • Wahba Khalil S.K.
        Sensitive high-pressure liquid chromatographic determination of disopyramide and mono-N-dealkyldisopyramide.
        J. Pharm. Sci. 1979; 68: 1318
        • Ochs H.R.
        • Carstens G.
        • Greenblatt D.J.
        Reduction in lidocaine clearance during continuous infusion and by coadministration of propranolol.
        N. Engl. J. Med. 1980; 303: 373
        • Ochs H.R.
        • Greenblatt D.J.
        • Woo E.
        Clinical pharmacokinetics of quinidine.
        Clin. Pharmacokinet. 1980; 5: 150
        • Ochs H.R.
        • Greenblatt D.J.
        • Woo E.
        • et al.
        Reduced quinidine clearance in elderly persons.
        Am. J. Cardiol. 1978; 42: 481
        • Opie L.H.
        Drugs and the heart.
        Lancet. 1980; 1: 693
        • Opie L.H.
        Antiarrhythmic agents.
        Lancet. 1980; 1: 861
        • Pfeifer H.J.
        • Greenblatt D.J.
        • Koch-Weser J.
        Clinical use and toxicity of intravenouslidocaine.
        Am. Heart J. 1976; 92: 168
        • Podrid P.J.
        • Schoeneberger A.
        • Lown B.
        Congestive heart failure caused by oral disopyramide.
        N. Engl. J. Med. 1980; 302: 614
        • Ranney R.E.
        • Dean R.R.
        • Karim A.
        • et al.
        Disopyramide phosphate: Pharmacokinetic and pharmacologic relationships of a new antiarrhythmic agent.
        Arch. Intern. Pharmacodyn. Ther. 1971; 191: 162
        • Reidenberg M.M.
        • Drayer D.E.
        • Levy M.
        • et al.
        Polymorphic acetylation of procainamide in man.
        Clin. Pharmacol. Ther. 1975; 17: 722
        • Rocco R.M.
        • Abbott D.C.
        • Giese R.W.
        • et al.
        Analysis for procainamide and N-acetylprocainamide in plasma or serum by high-performance liquid chromatography.
        Clin. Chem. 1977; 23: 705
        • Routledge P.A.
        • Shand D.G.
        Clinical pharmacokinetics of propranolol.
        Clin. Pharmacokinet. 1979; 4: 73
        • Rubenfeld S.
        • Silverman V.E.
        • Welch K.M.A.
        • et al.
        Variable plasma propranolol levels in thyrotoxicosis.
        N. Engl. J. Med. 1979; 300: 353
        • Shand D.G.
        Propranolol.
        N. Engl. J. Med. 1975; 293: 280
        • Shand D.G.
        Propranolol: Resolving problems in usage.
        Drug Ther. 1978; 53
        • Schneck D.W.
        • Prichard J.F.
        • Gibson T.P.
        • et al.
        Effect of dose and uremia on plasma and urine profiles of propranolol metabolites.
        Clin. Pharmacol. Ther. 1980; 27: 744
        • Singh B.N.
        • Vaughn Williams E.M.
        A fourth class of anti-dysrhythmic action? Effect of verapamil on ouabain toxicity, on atrial and ventricular intracellular potentials, and on other features of cardiac function.
        Cardiovasc. Res. 1972; 6: 109
        • Soeterboek A.M.
        Quinidine: Analytical, biopharmaceutical and pharmacokinetic aspects.
        Excerpta Medica. 1980; 501: 180
        • Sokolow M.
        • Ball R.E.
        Factors influencing conversion of chronic atrial fibrillation with special reference to serum quinidine concentrations.
        Circulation. 1956; 14: 568
        • Stargel W.W.
        • Roe C.R.
        • Routledge T.A.
        • et al.
        Importance of blood-collection tubes in plasma lidocaine determinations.
        Clin. 1979; 25: 617
        • Stone P.H.
        • Antman E.M.
        • Muller J.E.
        • et al.
        Calcium channel blocking agents in the treatment of cardiovascular disorders. Part II: Hemodynamic effects and clinical applications.
        Ann. Intern. Med. 1980; 93: 886
        • Story J.R.
        • Abdulla A.M.
        • Frank M.J.
        Cardiogenic shock and disopyramide phosphate.
        J. A. M. A. 1979; 242: 654
        • Strong J.M.
        • Dutcher J.S.
        • Lee W.
        • et al.
        Pharmacokinetics in man of the N-acetylatedmetabolite of procainamide.
        J. Pharmacokinet. Biopharm. 1975; 3: 223
        • Thomson P.D.
        • Melman K.L.
        • Ricardson J.A.
        • et al.
        Lidocaine pharmacokinetics in advanced heart failure, liver disease and renal failure in humans.
        Ann. Intern. Med. 1973; 78: 499
        • Ueda C.T.
        • Dzindzio B.S.
        Quinidine kinetics in congestive heart failure.
        Clin. Pharmacol. Ther. 1978; 23: 158
        • Ueda C.T.
        • Makoid M.C.
        Quinidine and dihydroquinidine interactions in humanplasma.
        J. Pharm. Sci. 1979; 68: 448
        • van der Pol W.S.C.J.M.
        Procainamide: Clinical, analytical and pharmacokinetic aspects.
        Excerpta Medica. 1980; 501: 172
        • Vismara L.A.
        • Vera Z.
        • Miller R.H.
        • et al.
        Efficacy of disopyramide phosphate in the treatment of refractory ventricular tachycardia.
        Am. J. Cardiol. 1977; 39: 1027
        • Walle T.
        • Conradi E.C.
        • Walle U.K.
        • et al.
        The predictable relationship between plasma levels and dose during chronic propranolol therapy.
        Clin. Pharmacol. Ther. 1978; 24: 668
        • Wesseling H.
        Clinical pharmacokinetics of lidocaine.
        Excerpta Medica. 1980; 501: 167
        • Woo E.
        • Greenblatt D.J.
        Effect of food on enteral absorption of quinidine.
        Clin. Pharmacol. Ther. 1980; 27: 188
        • Woo E.
        • Greenblatt D.J.
        Pharmacokinetic and clinical implications of quinidine protein binding.
        J. Pharm. Sci. 1979; 68: 466
        • Woosley R.L.
        • Drayer D.E.
        • Reidenberg M.M.
        • et al.
        Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome.
        N. Engl. J. Med. 1978; 298: 1157
        • Woosley R.L.
        • Shand D.G.
        Pharmacokinetics of antiarrhythmic drugs.
        Am. J. Cardiol. 1978; 41: 986
        • Yu P.N.
        Editorial: Disopyramide phosphate (Norpace): A new antiarrhythmic drug.
        Circulation. 1979; 59: 236

      Article info

      Identification

      DOI: https://doi.org/10.1016/S0272-2712(18)31087-4

      Copyright

      © 1981 Elsevier Inc. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX